(VIANEWS) - DMS IMAGING (BEL 20: DMSIM.BR) shares experienced a dramatic surge on Monday, increasing by 33.33% over just 21 trading sessions from EUR0.02 to EUR0.02, after experiencing a downward trend during its previous session when BEL 20 index fell by 0.35% to EUR3,670.13, yet DMS IMAGING posted two consecutive sessions of gains despite this downfall.
About DMS IMAGING
DMS Imaging SA, originally ASIT Biotech S.A, was founded in 1997 and based out of Liege, Belgium. Their lead product gp-ASIT+ is currently in Phase III trials for treating grass pollen allergy symptoms while house dust mite allergy treatment and peanut allergy treatment are in development stages as well.
Technical Analysis
DMS IMAGING stock has recently experienced fluctuations in volume and volatility that could wreak havoc with its stock price. Today's reported volume was 56,686 which was 27.11% below its average volume of 68,170 and may indicate there is little enthusiasm surrounding DMS IMAGING's share price at this time. Regarding volatility, the stock has seen an average intraday variation over the last week of positive 6.90% but a negative monthly variation of 1.13%; its positive quarterly variation rate indicates relative stability. The stochastic oscillator, an indicator that measures overbought and oversold conditions, indicates that DMS IMAGING's stock may currently be overbought (>=80). This could signal that its value may experience a correction soon. Overall, investors should keep tabs on DMS IMAGING's stock price and volume as well as its volatility indicators to make an informed decision about purchasing or selling this stock.
More news about DMS IMAGING (DMSIM.BR).